On the basis of the knowledge acquired on the genetics of ovarian cancer, the so-called HRD tests have been developed with the aim of identifying those tumors which, beyond the mutation of the BRCA1-2 genes, express a deficit of HR and against which a target therapy with PARP-inhibitors can be implemented. This evidence concerns the gene PARP1 and ovarian cancer.